Q1 EPS Forecast for Perspective Therapeutics Cut by Analyst

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at Brookline Capital Management cut their Q1 2025 earnings estimates for shares of Perspective Therapeutics in a note issued to investors on Wednesday, March 26th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.30) per share for the quarter, down from their prior estimate of ($0.29). Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($1.43) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($2.07) EPS.

CATX has been the subject of several other research reports. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. Royal Bank of Canada lowered their price target on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, March 27th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Monday. One analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $14.44.

Perspective Therapeutics Trading Down 3.2 %

Shares of Perspective Therapeutics stock opened at $2.13 on Monday. The business’s fifty day simple moving average is $2.91 and its 200 day simple moving average is $6.19. Perspective Therapeutics has a 12 month low of $2.01 and a 12 month high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

Large investors have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics in the 4th quarter worth about $33,000. Aigen Investment Management LP bought a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $34,000. National Bank of Canada FI grew its holdings in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after purchasing an additional 10,998 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after purchasing an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Perspective Therapeutics in the fourth quarter worth approximately $51,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.